Chuikyo Applies Medical Insurance To Regenerated Skin Product
This article was originally published in PharmAsia News
Executive Summary
Japan's Central Social Medical Insurance Agency (Chuikyo) decided Dec. 17 to include JACE regenerated skin as a reimbursable item for medical insurance beginning in January 2009. Manufactured and marketed by Aichi-based regeneration medical company Japan Tissue Engineering, JACE is priced at ¥306,000 per 80 square meters. The product uses a patient's own skin and treats patients with high class (over 30 percent of body) burns. After reimbursement, patients will be able to get the treatment for a fraction of the price, which otherwise could be as much as ¥10 million per month. Since the product obtained MHLW approval last October, a discussion over safety issues had delayed the reimbursement decision until now. (Click here for more - Japanese language
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.